Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Brief Summary: This randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.


Options:
A: Arm Label: Arm I (paclitaxel, doxorubicin, cyclophosphamide); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel | Arm Label: Arm II (paclitaxel, ddAC, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel | Arm Label: Arm III (paclitaxel, ddAC, carboplatin); Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel | Arm Label: Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (paclitaxel, ddAC, bevacizumab), Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm III (paclitaxel, ddAC, carboplatin), Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm I (paclitaxel, doxorubicin, cyclophosphamide), Arm II (paclitaxel, ddAC, bevacizumab), Arm III (paclitaxel, ddAC, carboplatin), Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin) | Intervention Type: DRUG; Name: Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (paclitaxel, doxorubicin, cyclophosphamide), Arm II (paclitaxel, ddAC, bevacizumab), Arm III (paclitaxel, ddAC, carboplatin), Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (paclitaxel, doxorubicin, cyclophosphamide), Arm II (paclitaxel, ddAC, bevacizumab), Arm III (paclitaxel, ddAC, carboplatin), Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (paclitaxel, doxorubicin, cyclophosphamide), Arm II (paclitaxel, ddAC, bevacizumab), Arm III (paclitaxel, ddAC, carboplatin), Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin)
B: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Trastuzumab, Drug: Pertuzumab | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trastuzumab, Drug: Pertuzumab, Drug: Paclitaxel | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Pertuzumab; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm B
C: Arm Label: Epirubicin and Cyclophosphamid followed by Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Cyclophosphamide, Drug: Docetaxel | Arm Label: Combination of Docetaxel and Cyclophosphamid; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Drug: Docetaxel | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): Epirubicin and Cyclophosphamid followed by Docetaxel | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Epirubicin and Cyclophosphamid followed by Docetaxel | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Epirubicin and Cyclophosphamid followed by Docetaxel | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Combination of Docetaxel and Cyclophosphamid | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Combination of Docetaxel and Cyclophosphamid
D: Arm Label: Induction Therapy; Type: EXPERIMENTAL; Interventions: Other: Induction therapy | Intervention Type: OTHER; Name: Induction therapy; Assigned to Arm(s): Induction Therapy

Answer: A